Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Grant of Restricted Share Units as part of TORM’s incentive program

The Board of Directors has as part of a long-term incentive program decided to grant certain employees (“Participants”) adjustment RSUs following exercise of 24,812 original RSUs granted in 2021 and 2022 to reflect the payment of dividend since the relevant grant date. The Participants will be granted a total of 2,671 RSUs in the form of restricted stock options. These adjustment RSUs will not be subject to further dividend adjustment and will have to be exercised within the same exercise window as they were issued. They will have a strike price of one US cent.   Transfer restrictions

Nomentia Appoints Huub Wevers as Chief Revenue Officer

Nomentia, a leading European treasury and cash management provider, is announcing the appointment of Huub Wevers as the new Chief Revenue Officer (CRO). This appointment aligns with Nomentia’s continued expansion across Europe, reinforcing its commitment to delivering exceptional value to its growing client base.Over the past four years, Nomentia has significantly expanded its footprint in Europe, starting from its core regions in Finland and Scandinavia. Following the establishment of Nomentia in 2020, the company acquired Tipco Treasury & Technology a year later, broadening its reach to

BPC Instruments adopts new Sustainability Policy

To clarify its ambitions in the field of sustainability, BPC Instruments AB (publ) has adopted a new Sustainability Policy. The policy serves to integrate environmental practices, social responsibility, and ethical governance into BPC Instruments operations.CEO at BPC, Dr. Jing Liu, comments: “Our new Sustainability Policy emphasizes innovation in the development of renewable bioenergy sources such as biogas and biohydrogen, the advancement of biodegradable polymer materials, and environmental bioanalysis. By integrating these sustainability practices into our core business strategy, we

iLOQ delivers smart access management to VodafoneZiggo

iLOQ’s battery-free and keyless smart-locking solution has been chosen to enhance access management for VodafoneZiggo. iLOQ, an innovative player in digital access management solutions, is to provide telecommunications and entertainment service provider, VodafoneZiggo, with its battery-free and keyless smart-locking solution. The mechanical locks on VodafoneZiggo’s telecom cabinets can be quickly and easily replaced with iLOQ’s battery-free cylinders without making any changes to the existing infrastructure. Access rights can be managed remotely leading to time and resource

Board-veteran and venture capitalist Arne Nabseth is up for election at White Pearl Technology Group’s next AGM

WPTG nominee committee proposes IT-entrepreneur and venture capitalist Arne Nabseth as a new board member. Nabseth’s experience and expertise are expected to support the company's future expansion plans. The vote will take place at the upcoming Annual General Meeting (AGM) on July 29th.“Arne Nabseth brings deep industry knowledge from SAP business, along with extensive experience as a CFO and CEO and is currently om several listed companies board of Directors. His multifaceted background in the IT-industry, business development and finance will support our mission to grow the company group.

BioStock: Lipum’s CEO comments on multiple-dose results in phase I

Following the positive single-dose results from the phase I study evaluating SOL-116, Lipum is now presenting additional promising data. The multiple-dose part of the study is now complete, and the safety profile continues to look good. Recruitment is currently ongoing for the third and final part, which involves rheumatoid arthritis patients.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/lipums-ceo-comments-on-multiple-dose-results-in-phase-i/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Lea bank ASA (LEA)- Mandatory notification of trades - primary insiders

Reference is made to today's stock exchange announcement regarding the capital increase. Chairman of the Board Rune Fjeldstad has subscribed for 27 401 shares. Following the completion, Fjelstad’s shareholding, including related parties, will be 55 763 shares. Board member Borghild Holen has subscribed for 14 901 shares. Following the completion, Holen's shareholding, including related parties, will be 21 290shares. Board member Viggo Leisner, through Duo Jag AS, has subscribed for 13 355 shares. Following the completion, Leisner's shareholding, including related parties, will be

Lea bank ASA - Resolution to increase the share capital, in connection with reinvestment of the remuneration to the board members

The Board of Directors of Lea bank ASA has on 20 June 2024 resolved to increase the share capital in connection with reinvestment of the remuneration to the board members. The capital increase will be made as a private placement of 68 256 shares with a nominal value of NOK 2.00 at a price of NOK 7,6 per share (volume weighted average price January to May, minus dividends during the period). As a result, the share capital will be increased by NOK 136 512 to NOK 191 034 776. The number of shares after the issue will be 95 517 388. Contact: Oddbjørn Berentsen, CEO Phone: +47 22 99 14 00

Technical News 9/24 – Spotlight Stock Market – launch of ETP trading June 25th

Spotlight Stock Market introduces ETPs with first day of trading on June 25th 2024. The ETPs will now be added in INET production. ETPs are traded in a new market segment, Spotlight Sweden Tracker Certificates, SPSE TRA.  Symbol VALOUR HBAR SEK VALOUR CORE SEKISIN  CH1213604585 CH1213604593Orderbook ID To be provided To be providedCFI EYAYFM EYAYFMMarket XSAT XSAT Additional information such as trading schedule, market data, protocols, are found in: · Nasdaq IT - INET Nordic (40/24). · Spotlight Stock

CLS receives additional order for ClearPoint Prism products corresponding to approximately SEK 7.5 million

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT). The order, which has a value of approximately SEK 7.5 million, is for ClearPoint Prism products and is part of ClearPoint Neuro's full market launch in North America, which began in early June this year, and follows previous orders that CLS received around the turn of the year 2023/2024 totaling approximately SEK 10.5 million.­­ CLS's collaboration with ClearPoint Neuro Inc aims to develop and

Gaming Innovation Group signs platform agreement to expand Ontario market footprint

Gaming Innovation Group (GiG) has announced the signing of a Head of Terms with Ventures Lab, for the provision of its award winning iGaming platform, and AI tools DataX and LogicX, marking the fourth platform partner for GiG in the Canadian province and supporting GiG’s global strategy for regulated market growth. The agreement with Ventures Lab in Ontario will fully utilise the capability of the platform and the ability to support speed to market. GiG’s experience in Ontario and in global regulated markets, and as exclusive regulated markets provider for the brand, the deal includes

Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm

The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical developmentCinclus Pharma Holding AB (publ) (“Cinclus Pharma”) is a Swedish late-stage pharmaceutical company committed to improving the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide. The company is targeting two main clinical indications; GERD (Gastroesophageal reflux disease) and H. pylori infection. Cinclus Pharmas’ drug candidate, linaprazan glurate, is a proprietary prodrug of the molecule linaprazan, originally developed by AstraZeneca.

Announcement of the terms for the offering of shares and subsequent admission to trading on Euronext Growth Oslo

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Hamilton, Bermuda, 20 June 2024: Reference is made to the announcement by Paratus Energy Services Ltd. (“Paratus” or the “Company”) dated 19 June 2024 regarding the intention to launch a private placement of new shares in the Company (the "Offering") and to list the Company’s shares on Euronext Growth Oslo (the “Listing”).

JM selling rental property in Järfälla, Stockholm

JM has signed an agreement for the sale of a rental property located in Järfälla, Stockholm. The transaction amounts to SEK 497m.The property being sold is the project Flora, which consists of 155 residential units and is part of the larger development area Söderdalen in central Järfälla, where JM implements housing projects with various forms of tenure. The property is under construction with a planned transfer of legal title in the third quarter of 2025, which is when construction is expected to be completed.   Starting in the second quarter of 2024, the revenue and profit from the

STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO The Stenocare TO2 Warrant subscription will end at the close of business on June 21. To benefit from the discounted share price of DKK 3.16 each, owners of TO2 Warrants must exercise their warrants before the deadline.Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. Owners can subscribe (ie. purchase) new Stenocare shares at a discounted price of DKK 3.16 each. The deadline for subscription at the discounted price is June 21, 2024, at 17:00 Central European Summer Time. TO2

Transaction in Own Shares

    20 June 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |19/06/2024|+--------------------------------------------------------------

Biokraft plans biogas investment in Perstorp Industrial Park

Biokraft, a leading player in Nordic biogas production, has signed an exclusive land agreement with the industrial group Perstorp where Biokraft is given the opportunity to design a biogas plant at the Group's industrial park in Perstorp. The plant's capacity is planned to be 130 GWh of biomethane and 17,000 tonnes of liquid CO\2\ per year and is expected to be completed in 2027.Biokraft's long-term goal is to expand its existing production capacity of 585 GWh per year to 3 TWh by 2030. The recently signed agreement to design a biogas plant at Perstorp's industrial park is a step towards

Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering

Faron Pharmaceuticals Ltd (“Faron” or the “Company”) Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.   THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO

Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a video interview by BioStock has been released with CEO Sten R. Sörensen, commenting on the approval by the EMA for a first-in-human Phase I trial of novel histone deacetylase inhibitor (HDACi) CS014, why this is such an important milestone for Cereno, and the potential of HDAC inhibition as a concept in cardiovascular disease.Watch here: Cereno Scientific brings novel cardiovascular disease candidate to the clinic (youtube.

LAUNCH OF VOLUNTARY OFFER AND COMMENCEMENT OF OFFER PERIOD FOR ALL ISSUED AND OUTSTANDING SHARES IN KYOTO GROUP AT NOK 24 PER SHARE; OFFER ACCEPTANCE DEADLINE AT 16:30 CET ON 27 June 2024.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Reference is made to the announcement made by Kyoto Group AS ("Kyoto" or the "Company") on 14 June 2024 concerning the transaction agreement entered into by the Company and GF I Kiln HoldCo AS (the "Offeror") regarding a directed share issue in the Company (the "Investment") combined with a recommended voluntary all-cash offer for all outstanding shares (the "

BioStock: Cereno's CEO – "CS014 adds potential for cardiovascular disease patients"

Cereno Scientific is a biotech company developing treatments for the number one killer in the world - cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.Read the interview at biostock.se: Cereno's CEO: "CS014 adds potential for cardiovascular disease patients" - BioStock 

There are no items matching the current filter
There are no more items matching the current filter
Back to top